Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
BERGERON, Anne
RXC007 0002, NCT05570058 / 2022-000498-15: Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Jan 2024 - Mar 2024 : Q1'24 - Topline data from trial for IPF	Active, not recruiting	2	48	Europe, RoW	RXC007, Placebo	Redx Pharma Plc, Simbec-Orion Group	IPF, Fibrosis	06/24	01/25
Semac, Isbelle
RXC007 0002, NCT05570058 / 2022-000498-15: Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Jan 2024 - Mar 2024 : Q1'24 - Topline data from trial for IPF	Active, not recruiting	2	48	Europe, RoW	RXC007, Placebo	Redx Pharma Plc, Simbec-Orion Group	IPF, Fibrosis	06/24	01/25
Valli, Eloise
RXC007 0002, NCT05570058 / 2022-000498-15: Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Jan 2024 - Mar 2024 : Q1'24 - Topline data from trial for IPF	Active, not recruiting	2	48	Europe, RoW	RXC007, Placebo	Redx Pharma Plc, Simbec-Orion Group	IPF, Fibrosis	06/24	01/25